Diabetes Care Journal

Overview
Identity
View All

publication venue for

Oral Glucose Tolerance Test Results in Pregnancy Can Be Used to Individualize the Risk of Future Maternal Type 2 Diabetes Mellitus in Women With Gestational Diabetes Mellitus. 44:1860-1867. 2021
Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 2016;39:1186–1201. 40:e23-e24. 2017
Making a Difference With Diabetes Research and Care. 39:1309-1310. 2016
Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. 39:780-787. 2016
Comment on Hempe et al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. Diabetes Care 2015;38:1067–1074. 38:e170-e171. 2015
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes. 38:1558-1566. 2015
Cognitive Function and the Risk for Diabetes Among Young Men. 37:2982-2988. 2014
Response to Suissa and Azoulay. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366. 37:e217-e217. 2014
Response to Zanders et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366. 37:e223-e223. 2014
The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. 37:1360-1366. 2014
Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study. 37:604-610. 2014
Short Leg Length, a Marker of Early Childhood Deprivation, Is Associated With Metabolic Disorders Underlying Type 2 Diabetes. 36:3599-3606. 2013
Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial. 36:1266-1271. 2013
Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes. 35:787-793. 2012
Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes. 35:749-753. 2012
Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit. 35:19-24. 2012
Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes. 34:1902-1907. 2011
Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes (vol 33, pg 1379, 2010). 34:247-247. 2011
Patient Age, Ethnicity, Medical History, and Risk Factor Profile, but Not Drug Insurance Coverage, Predict Successful Attainment of Glycemic Targets Time 2 Do More Quality Enhancement Research Initiative (T2DM QUERI). 33:2558-2560. 2010
Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance. 33:1629-1634. 2010
Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. 33:608-613. 2010
Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. 31:1007-1014. 2008
A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events. 30:389-394. 2007
Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach. 30:432-434. 2007
Metabolic Syndrome. 29:2471-2476. 2006
The Burden of Treatment Failure in Type 2 Diabetes. 28:761-762. 2005
The Effect of Vitamin E Supplementation on Cardiovascular Risk in Diabetic Individuals With Different Haptoglobin Phenotypes. 27:2767-2767. 2004
Utility of B-Type Natriuretic Peptide (BNP) as a Screen for Left Ventricular Dysfunction in Patients With Diabetes. 26:2081-2087. 2003
A Randomized Trial of an Intervention to Improve Self-Care Behaviors of African-American Women With Type 2 Diabetes. 25:1576-1583. 2002
Fasting Versus Postload Glucose Levels. 24:1855-1857. 2001
Cardiovascular and metabolic benefits of ACE inhibition: moving beyond blood pressure reduction.. 23:882-883. 2000
Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators.. 23 Suppl 2:B35-B39. 2000
Is glucose a continuous risk factor for cardiovascular mortality?. 22:659-660. 1999
Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis.. 22 Suppl 2:B35-B39. 1999
Growth factors and the regulation of fetal growth.. 21 Suppl 2:B60-B69. 1998
Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study. 19:1225-1228. 1996
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.. 19:1225-1228. 1996
Feasibility and Acceptability of a Proposed Infant Feeding Intervention Trial for the Prevention of Type I Diabetes. 18:940-942. 1995
Cow's Milk Exposure and Type I Diabetes Mellitus: A critical overview of the clinical literature. 17:13-19. 1994

has subject area

11 Medical and Health Sciences (FoR)
Endocrinology & Metabolism (Science Metrix)